Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18352683 | 0.95 | ZDHHC2 (0.52) | ZDHHC2NPC1GAARAB9ATAAR1 | |
| SCHEMBL18354871 | 0.92 | TAAR1 (0.50) | ZDHHC2NPC1GAARAB9ATAAR1 | |
| SCHEMBL18355458 | 0.91 | ZDHHC2 (0.53) | ZDHHC2L3MBTL1RECQL | |
| SCHEMBL18354884 | 0.88 | ZDHHC2 (0.47) | ZDHHC2NPC1GAARAB9ATAAR1 | |
| SCHEMBL18352553 | 0.86 | ZDHHC2 (0.48) | ZDHHC2NPC1GAARAB9ATAAR1 | |
| SCHEMBL18354925 | 0.83 | HTT (0.59) | L3MBTL1 | |
| SCHEMBL18355438 | 0.83 | MAPT (0.51) | ZDHHC2NPC1GAARAB9ATAAR1 | |
| SCHEMBL18406536 | 0.81 | ALDH1A1 (0.56) | NPC1RAB9AHPGD | |
| SCHEMBL18354907 | 0.80 | ATM (0.50) | RAB9A | |
| SCHEMBL18354880 | 0.80 | NPC1 (0.47) | ZDHHC2NPC1GAARAB9ATAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170001953-A1 | FUMARATE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | Nguyen, Mark Quang (US) | 2017-01-05 | — | — | US | disclosed |
| US-20170001953-A1 | FUMARATE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | Nguyen, Mark Quang (US) | 2017-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170001953-A1 | FUMARATE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | FH, FPGS, APC | ZDHHC2 153/4885NPC1 2073/4885GAA 418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.